CIRM / Regenerative Medicine Consortium
Webinar: Preclinical Considerations for Stem Cell Therapies
Presented by RMC, FDA and Industry Leaders
CIRM will host this webinar as the sponsor of the Regenerative Medicine Consortium’s (RMC’s) webinar series on IND readiness. The mission of the RMC is to accelerate the development and regulatory approval of stem cell and regenerative medicine therapies.
For more information please see the Regenerative Medicine Consortium page.
Webinar Topic & Agenda
Preclinical Considerations for Stem Cell Therapies
- Regulatory review principles
- Adult stem cell (allogeneic and autologous) and hESC derived therapies to be presented
- Lessons learned
Moderator: Elona Baum, CIRM, General Counsel and RMC Chair
For additional information please contact: email@example.com
- Mercedes Serabian, M.S., DABT, Chief, Pharmacology/Toxicology Branch (PTB), Division of Clinical Evaluation & Pharmacology/Toxicology (DCEPT), Office of Cellular, Tissue and Gene Therapies (OCTGT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA) See Slides [pdf]
- Robert Deans, PhD., Senior Vice President Regenerative Medicine, Athersys, Inc. See Slides [ppdf]
- Melissa Carpenter, PhD., Carpenter Group See Slides [pdf]